Kanjinti (trastuzumab-anns), a biosimilar for Herceptin used to treat people diagnosed with HER2-positive breast cancer, is now available in the United States.
While two large studies suggest that intraoperative radiation therapy offers about the same overall survival and rates as whole-breast external beam radiation therapy for certain women diagnosed with early stage-breast cancer, there are concerns about local recurrence rates.
A research letter estimates that modern radiation therapy techniques are less likely to cause heart problems than radiation therapy techniques used 20 or more years ago.
To provide practical approaches to managing cancer pain, the American Society of Clinical Oncology (ASCO) developed a special series of 14 articles on pain in people with cancer, including breast cancer.
People newly diagnosed with non-metastatic breast cancer who switched their care to a different doctor had various treatments delayed by more than a week.
Only about 25% of women diagnosed with breast cancer and about 31% of women diagnosed with ovarian cancer have genetic testing.
A small study suggests that postmenopausal women with partners may have better quality of life than women without partners when experiencing a number of sexual side effects from hormonal therapy.
Latest MONALEESA-3 results show Kisqali and Faslodex offer better overall survival than Faslodex alone in postmenopausal women diagnosed with advanced-stage, hormone-receptor-positive, HER2-negative breast cancer that either hadn't been treated yet or had been treated with only one hormonal therapy.
The combination of the immunotherapy Keytruda and chemotherapy before surgery to remove early-stage, triple-negative breast cancer led to a better pathologic complete response than chemotherapy alone.
A large study has found that bisphosphonates reduce the risk of distant breast cancer recurrence in postmenopausal women.
A new study has found that exercise eases joint pain that's a common side effect of aromatase inhibitors.
An analysis of three studies on different CDK4/6 inhibitors in combination with an aromatase inhibitor to treat postmenopausal women diagnosed with metastatic, hormone-receptor-positive, HER2-negative breast cancer found the treatment combination was effective in both younger and older women.
Adding experimental tucatinib to the standard of care of Herceptin and Xeloda improved both progression-free survival and overall survival in people diagnosed with metastatic HER2-positive breast cancer that had been previously treated with Herceptin, Perjeta, and Kadcyla.
A large study suggests that there is no link between vitamin D and overall survival or disease-free survival in women diagnosed with breast cancer with a high risk of recurrence. Still, there are questions about the study.
A small study suggests that changes in brain activity may be the cause of chemo brain.
Results from two studies on using the immunotherapy medicines Tecentriq or Keytruda along with chemotherapy to treat early-stage triple-negative breast cancer before surgery suggested that Keytruda offered benefits while Tecentriq did not.
Five-year results found women diagnosed with early-stage, hormone-receptor-negative breast cancer who were treated with Zoladex in addition to chemotherapy before surgery were much less likely to be infertile after chemotherapy ended.
A national survey of more than 1,000 women diagnosed with metastatic breast cancer found that 35% had no insurance and nearly 70% said they were worried about financial problems because of cancer.
A study suggests that a drug that is a biosimilar to Herceptin, called MYL-1401O, is as effective as Herceptin and has similar side effects.
A study has found that women diagnosed with early-stage, hormone-receptor-positive breast cancer with no prescription drug coverage were less likely to start hormonal therapy than women who had insurance coverage for prescription drugs.
Women diagnosed with early-stage, HER2-positive breast cancer treated with both Herceptin and Tykerb after surgery had the same disease-free survival as women treated with only Herceptin after surgery.
Two studies presented at the 2015 San Antonio Breast Cancer Symposium suggest that adding carboplatin to the standard neoadjuvant chemotherapy regimen may improve outcomes for women diagnosed with triple-negative disease.
A study has found that Prolia improved disease-free survival for postmenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer taking an aromatase inhibitor.
Another study suggests that lumpectomy plus radiation may offer survival benefits for some women diagnosed with early-stage disease.